Catecholaminergic polymorphic ventricular tachycardia MedDRA version: 14.1 Level: LLT Classification code 10036095 Term: Polymorphic ventricular tachycardia System Organ Class: 100000004849
Conditions
Interventions
Trade Name: Dantrium
Product Name: Dantrium
Pharmaceutical Form: Powder for infusion
CAS Number: 14663-23-1
Other descriptive name: DANT
Sponsors
Heikki Swan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Exercise-provoked premature ventricular complexes RYR2 mutation Age>17 On-going treatment with betablockers Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 4 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 2
Exclusion criteria
Exclusion criteria: calcium-channel blocker or metoclopramide medication, inability to do exercise-stress test with bicycle, systolic blood pressure over 160 or diastolic over 95 mmHg, clinically significant angina pectoris or valvular disease, congenital heart disease At resting ECG PQ interval >200 ms, QRS>120 ms, LVH, pre-excitation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Assess the antiarrhythmic effects of dantrolene;Secondary Objective: Assess the effects of dantrolene on cardiac repolarization;Primary end point(s): at each minute of exercise: heart rate, number of premature ventricular complexes, number of longest ventricular salvo during exercise stress test after study drug infusion;Timepoint(s) of evaluation of this end point: at each minute of exericse | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): duration of the exercise in minutes sinus rate at the end of each minute achieved maximum sinus rate ;Timepoint(s) of evaluation of this end point: First eight minutes of the recovery phase | — |
Countries
Finland
Contacts
Public ContactHelsinki University Hospital
Heikki Swan
Outcome results
None listed